Book IGF-1 Test in Bhavnagar | Insulin Like Growth Factor 1

The Insulin Like Growth Factor 1 test is a blood test that measures the level of IGF-1, a peptide hormone produced predominantly by the liver in response to growth hormone stimulation from the anterior pituitary gland. IGF-1 mediates the majority of the growth-promoting and anabolic effects of growth hormone on peripheral tissues including bone, muscle, cartilage, and organs, stimulating cell proliferation, protein synthesis, and longitudinal skeletal growth during childhood and adolescence. Unlike growth hormone itself, which is secreted in pulsatile bursts with wide intraday variability making single measurements unreliable, IGF-1 has a relatively stable concentration throughout the day reflecting the integrated growth hormone secretory activity over the preceding 24 hours, making it the preferred and most clinically reliable surrogate marker of growth hormone axis activity. IGF-1 is produced in response to growth hormone stimulation and its synthesis requires adequate nutritional status, insulin availability, and hepatic function. Levels follow a characteristic age-related trajectory, remaining low in infancy, rising progressively through childhood, peaking during the pubertal growth spurt when growth hormone secretion is highest, and then declining progressively through adulthood and advancing age. This age-dependent variation means that IGF-1 results must always be interpreted against age-matched and gender-matched reference ranges rather than a single universal normal range. In India, growth disorders in children including short stature, growth failure, and precocious growth are common presentations in paediatric endocrinology practice, while acromegaly and growth hormone deficiency in adults are increasingly recognised conditions that were historically underdiagnosed due to limited diagnostic awareness. The test is performed on a small blood sample drawn from a vein and completed in under five minutes.

Doctors prescribe an IGF-1 test in the following situations: Investigating short stature and growth failure in children where height velocity is below the expected centile for age and gender, and where IGF-1 measurement alongside growth hormone stimulation testing helps identify growth hormone deficiency as a treatable cause of impaired linear growth requiring recombinant growth hormone therapy. Diagnosing acromegaly in adults with characteristic features including enlargement of the hands, feet, and facial features, coarsening of facial appearance, jaw prognathism, increased sweating, sleep apnoea, joint pain, and new-onset diabetes where a markedly elevated IGF-1 is the primary screening investigation confirming growth hormone excess before confirmatory oral glucose tolerance testing and pituitary MRI. Monitoring acromegaly treatment response in patients undergoing pituitary surgery, radiation therapy, or medical therapy with somatostatin analogues or growth hormone receptor antagonists where serial IGF-1 measurements are the primary biochemical endpoint for assessing disease control and guiding treatment modifications to achieve normalisation of growth hormone axis activity. Evaluating growth hormone deficiency in adults presenting with reduced muscle mass, increased central adiposity, fatigue, impaired quality of life, and reduced bone density where IGF-1 measurement provides an initial screening assessment before formal growth hormone stimulation testing is performed to confirm the diagnosis and determine eligibility for adult growth hormone replacement therapy. Assessing delayed puberty and pubertal growth disorders in adolescents where IGF-1 measurement alongside bone age assessment and gonadotropin levels characterises the hormonal status of the growth axis and distinguishes constitutional growth delay from pathological growth hormone or gonadal deficiency requiring treatment. Monitoring growth hormone replacement therapy in children and adults where serial IGF-1 measurements during treatment guide dose titration to maintain IGF-1 within the age-appropriate normal range, ensuring therapeutic efficacy while avoiding supraphysiological levels associated with potential adverse effects including insulin resistance and theoretical malignancy risk.

The IGF-1 test measures the concentration of Insulin Like Growth Factor 1 in the blood serum, expressed in nanograms per millilitre (ng/mL) or micrograms per litre (mcg/L). Reference ranges are highly age-dependent and gender-dependent, varying enormously across the lifespan from very low levels in early childhood through peak pubertal values to declining adult levels. Approximate adult reference ranges are 115 to 355 ng/mL for adults aged 20 to 40 years, declining to 70 to 220 ng/mL in adults over 60 years. Pubertal children may have levels two to three times higher than adult values at peak growth velocity. Results must always be interpreted against the laboratory's age and gender specific reference range. Normal for Age and Gender A result within the age and gender appropriate reference range indicates that the growth hormone axis is functioning within expected physiological limits at the time of testing. In the context of suspected acromegaly, a normal IGF-1 effectively excludes the diagnosis in most cases. In suspected growth hormone deficiency, a low normal IGF-1 may still warrant formal growth hormone stimulation testing if clinical suspicion remains high based on symptoms and other investigations. Low IGF-1 A low IGF-1 result indicates reduced growth hormone axis activity and may reflect growth hormone deficiency from pituitary pathology, hypothalamic dysfunction, malnutrition, chronic liver disease, uncontrolled diabetes, hypothyroidism, or inflammatory conditions that suppress IGF-1 synthesis independently of growth hormone secretion. In children, low IGF-1 with low height velocity warrants formal growth hormone stimulation testing to confirm or exclude growth hormone deficiency as an indication for recombinant growth hormone therapy. Elevated IGF-1 An elevated IGF-1 result above the age and gender appropriate reference range indicates excess growth hormone axis activity and is the hallmark biochemical finding in acromegaly in adults and gigantism in children. Markedly elevated IGF-1 requires confirmatory oral glucose tolerance testing with growth hormone measurement and pituitary MRI for tumour localisation before surgical or medical treatment planning under specialist endocrinological care.

No fasting is strictly required for the IGF-1 test alone, as IGF-1 levels are relatively stable throughout the day and are not significantly influenced by individual meals. However since IGF-1 is frequently ordered alongside fasting glucose, insulin, thyroid function, and other metabolic or pituitary hormones as part of a comprehensive endocrine panel, fasting for 8 hours before collection is generally recommended to ensure accuracy of all co-ordered investigations. Nutritional status significantly influences IGF-1 levels, with malnutrition, prolonged caloric restriction, and eating disorders causing IGF-1 suppression independent of growth hormone secretory status. Inform your doctor if you have been following a severely calorie-restricted diet, have experienced significant recent weight loss, or have a history of an eating disorder, as these nutritional factors must be considered when interpreting a low IGF-1 result to avoid misattributing nutritional suppression to growth hormone deficiency. Inform your doctor about all medications currently being taken, particularly growth hormone injections, insulin, oral contraceptives, glucocorticoids, and somatostatin analogues, as these directly alter IGF-1 levels and are essential context for accurate clinical interpretation. If you are a child or adolescent being tested, accurate recording of height, weight, bone age, and pubertal stage at the time of testing is critically important as these parameters are essential for contextualising the IGF-1 result against appropriate age and pubertal stage specific reference ranges. Staying well hydrated before the blood draw facilitates easier venous access and a smooth collection experience.

If you are booking through the SecondMedic platform the IGF-1 test price in Bhavnagar can cost you around Rs. 902. You may also consider booking a comprehensive growth hormone axis panel that includes IGF-1 alongside IGFBP-3, fasting growth hormone, thyroid function, and bone age assessment for a complete evaluation of growth disorders in children or acromegaly screening in adults at a bundled price on SecondMedic.

SecondMedic offers convenient home sample collection for the IGF-1 test in Bhavnagar, making it easy to get tested without visiting a diagnostic centre. Home collection is available free of charge for orders above Rs. 300. A trained phlebotomist will visit your preferred address between 7 AM and 10 PM, seven days a week, including Sundays and public holidays. Your blood sample is processed at NABL-accredited partner laboratories, and your report is delivered within 24 hours directly to your WhatsApp and email.